Overview of Parkinson's disease

Pharmacotherapy

Volumn 27, Issue 12 II, 2007, Pages

  Lew, Mark ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diagnosis; Management; Parkinson's disease; Pharmacotherapy

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PETHIDINE;

ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; BRADYKINESIA; BRAIN DEPTH STIMULATION; CEREBELLUM DISEASE; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; ESSENTIAL TREMOR; GAIT DISORDER; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; QUALITY OF LIFE; REVIEW; RIGIDITY; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TREMOR;

EID: 36849086854     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.12part2.155s     Document Type: Review

References (33)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93.
2. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005;353:1021-7.
3. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000;54(11 suppl 5):S21-3.
4. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam study. Neurology 2004;63:1240-4.
5. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-49.
6. Hague SM, Klaffke S, Bandmann O. Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry 2005;76:1058-63.
7. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001;86:122-7.
8. Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson's disease. J Neurol Sci 2004;217:169-74.
9. Frigerio R, Sanft KR, Grossardt BR, et al. Chemical exposures and Parkinson's disease: a population-based control study. Mov Disord 2006;21:1688-92.
10. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson's disease. J Neural Transm Suppl 2006;70:147-51.
11. Inzelberg R, Schectman E, Paleacu D. Onset age of Parkinson disease. Am J Med Genet 2002;111:459-60.
12. Rao S, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006;74:2046-56.
13. Weiner WJ. A differential diagnosis of parkinsonism. Rev Neurol Dis 2005;2:124-31.
14. Uitti RJ, Baba Y, Whaley NR, et al. Parkinson disease: handedness predicts asymmetry. Neurology 2005;64:1925-30.
15. Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA 2003;289:347-53.
16. Golbe LI. Progressive supranuclear palsy. In: Beal MF, Lang AE, Ludolph AC, eds. Neurodegenerative diseases: neurobiology, pathogenesis and therapeutics. New York: Cambridge University Press, 2005:663-81.
17. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-75.
18. Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry 2006;21:252-8.
19. Frank MJ. Dynamic dopamine metabolism in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cogn Neurosci 2005;17:51-72.
20. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45.
21. Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin 2005;23:1187-208.
22. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
23. 10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8.
24. The National Institute of Neurological Disorders and Stroke, NIH Exploratory Trials in Parkinson Disease (NINDS NET-PD) Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-71.
25. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006;66:628-33.
26. Volkmann J. Update on surgery for Parkinson's disease. Curr Opin Neurol 2007;20:465-9.
27. Takahashi J. Stem cell therapy for Parkinson's disease. Expert Rev Neurother 2007;7:667-75.
28. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25.
29. Müller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 2001;58:259-64.
30. Poewe W. Natural history and prognosis of Parkinson's disease. In: Mizuno Y, Fisher A, Hanin I, eds. Mapping the progress of Alzheimer's and Parkinson's disease. New York: Kluwer Academic, 2002:325-9.
31. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-6.
32. Rascol O, Olanow W. ADAGIO: a prospective, double-blind, delayed-start study to examine the potential disease-modifying effect of rasagiline in Parkinson's disease. Presented at the Movement Disorder Society's 10th international congress of parkinson's disease and movement disorders, Kyoto, Japan, October 28-November 2, 2006.
33. Morgan JC, Sethi KD. Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs 2006;11:403-17.